News

October 2021
Import license; submitted in India. The company filed an application for the registration of RegenoGel in India

Import license; submitted in India. The company filed an application for the registration of RegenoGel in India

October 2021
ICRS 2022 Berlin World Congress – Abstract Submission

ICRS 2022 Berlin World Congress – Abstract Submission.

Procore has submitted an abstract to participate in a large-scale congress of a unique worldwide forum for cartilage regeneration and joint preservation.

March 2021
Procore extends distribution of Regenogel-OSP to private clinics and medical centers in Israel

Procore extends distribution of Regenogel-OSP to private clinics and medical centers in Israel.

RegenoGel-OSP is an autologous version of RegenoGel with an added layer of personalized properties. RegenoGel-OSP (On Site Plasma) combines high molecular weight hyaluronic acid (HA) with the patient’s own plasma.

January 2021
Signed agreement with a local distributer to import the product to Vietnam

Distribution agreement; Vietnam. Signed agreement with a local distributer to import the product to Vietnam following Product Registration and import license to the territory.

January 2021
ISO 13845 accreditation granted to Procore’s manufacturing facility, enabling production of RegenoGel

Quality certificate for Regenogel Production facility extended. ISO 13845 accreditation granted to Procore’s manufacturing facility, enabling production of RegenoGel. The company also received a Free Sale Certificate for exporting RegenoGel worldwide.

December 2020
Procore signs a distribution agreement with a multinational distribution company with presence in the Ukraine

Distribution agreement for the Ukraine. Procore signs a distribution agreement with a multinational distribution company with presence in the Ukraine towards registration of Regenogel with the official Ukrainian Medicines Authority.

November 2020
Procore signs a Distribution agreement with a local Chinese company, in collaboration with the largest pharmaceutical distributor in China.

Procore signs a Distribution agreement with a local Chinese company, in collaboration with the largest pharmaceutical distributor in China. The company has committed to complete regulatory and CFDA guided trials within 18 months and begin distributing and selling RegenoGel in greater China in the second quarter of 2022.

Leave your details

    and we will return to you ASAP!